徳島大学 教育・研究者情報データベース(EDB)

1. (英) Sagawa Tamotsu

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 佐藤 康史([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Hirakawa Masahiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Hamaguchi Kyoko

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. (英) Fukuya Akira / (日) 福家 慧 / (読) ふくや あきら

   役割	任意
   貢献度	任意
   学籍番号	推奨	****

6. 岡本 耕一([徳島大学.病院.診療科.内科.消化器内科])

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. 宮本 弘志([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学]/[徳島大学.病院.診療科.内科.消化器内科])

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. 六車 直樹

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Fujikawa Koshi

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Takahashi Yasuo

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. 高山 哲治([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.

(英) The primary tumour location is an important prognostic factor for previously untreated metastatic colorectal cancer (mCRC). However, the predictive efficacies of primary tumour location, early tumour shrinkage (ETS), and depth of response (DpR) on mCRC treatment has not been fully evaluated. This study aimed to investigate the predictive efficacies of these traits in mCRC patients treated with first-line 5-fluorouracil-based chemotherapy plus biologic agents, namely, cetuximab and bevacizumab. This was a retrospective analysis of the medical records of 110 patients with pathology-documented unresectable mCRC. Patients with left-sided mCRC receiving any first-line regimen showed better overall survival (OS) than those with right-sided mCRC [33.3 vs 16.3 months; hazard ratio (HR) 0.44; 95% confidence interval (CI) 0.27-0.74; p < 0.001]. In patients with left-sided tumours, treatment with chemotherapy plus cetuximab yielded longer OS than chemotherapy plus bevacizumab (50.6 vs 27.8 months, HR 0.55; 95% CI 0.32-0.97; p = 0.0378). mCRC patients with ETS and high DpR showed better OS than those lacking ETS and with low DpR (33.5 vs 19.6 months, HR 0.50, 95% CI 0.32-0.79, p = 0.023 and 38.3 vs 19.0 months, HR 0.43, 95% CI 0.28-0.68, p < 0.001, respectively). Moreover, ETS and/or high DpR achieved in patients with right-sided mCRC receiving chemotherapy plus cetuximab were associated with significantly better OS than in those lacking ETS and with low DpR (34.3 vs 10.4 months, HR 0.19, 95% CI 0.04-0.94, p = 0.025 and 34.3 vs 10.4 months, HR 0.19, 95% CI 0.04-0.94, p = 0.0257, respectively). Taken together, our study demonstrates that primary tumour location is not only a well-known prognostic factor but also a relevant predictive factor in patients with mCRC receiving chemotherapy plus cetuximab. Additionally, both ETS and DpR could predict treatment outcomes and also potentially guide cetuximab treatment even in right-sided mCRCs.

1. (英) Article.ELocationID: 10.1038/s41598-020-76756-1

2. (英) Article.PublicationTypeList.PublicationType: Journal Article